Level C· Early human research exploring benefitsRetrospective StudyPubMedOpen access

The role of arthroscopy in intra-articular adipose tissue-derived mesenchymal stem cells for the treatment of early-stage knee osteoarthritis: A bicentric retrospective comparative study.

Giusti S., Adriani E., Samuelsson K., Laudisio A., Horvath A., Zampogna B.

Retrospective Study with a reported sample of 68 on Knee Osteoarthritis, Osteoarthritis, Cartilage Damage, published in J Exp Orthop (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Retrospective Study
Journal
J Exp Orthop (2025)
Country
United States
Reported sample size
68
Source database
PubMed
PMID
40693217
PMCID
PMC12277641
DOI
10.1002/jeo2.70368

Abstract (original English)

To determine the difference in clinical scores and re-intervention rates in patients receiving intra-articular adipose-derived mesenchymal stromal cells (AD-MSCs) as a stand-alone treatment for knee osteoarthritis (OA) compared to patients receiving the same treatment following arthroscopic debridement and lavage. Internal records at two orthopaedic centres were reviewed, and all consecutive patients with Kellgren-Lawrence II-III knee OA who had received intra-articular AD-MSC during 2017-2018 were included. The patients were stratified into two cohorts depending on whether they also received debridement arthroscopy. Patients were evaluated with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and visual analogue scale (VAS) scores as well as re-intervention rates with a last available follow-up of 5 years after the intra-articular AD-MSC injection. A total of 135 patients were enroled, 66 (49%) patients were male and 69 (51%) were female. The mean age at the time of intervention was 66 (range: 43-81) years. About half of the cohort ( n = 68) received a diagnostic and therapeutic arthroscopy (intervention) procedure in the same setting, whereas the other half ( n = 67) received intra-articular AD-MSCs without an arthroscopic procedure (control). Totally, 94% reported improved VAS scores post-operatively. Seventy-two patients (53%) had good symptomatic

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • Without an adequate control group, treatment effects cannot be separated from other factors.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research